• iPSC Generation from Your Samples
    • PBMC, fibroblasts
    • Sample collection available
    iPSC Generation from Your Samples

iPSC Generation from Patient Samples

iPSC Generation is a complex process that reprograms adult somatic cells into a pluripotent, embryonic stem cell-like stage. This requires extensive technical expertise to generate cells that are robust, karyotype-normal, and pluripotent. With >12 years expertise in stem cell technologies and as a leading provider of iPSC services, Applied StemCell can generate iPSCs for you very efficiently and successfully::

  • Healthy/ disease samples
  • From a variety of starting tissues: PBMCs, fibroblasts, cord blood, HSC, MSC, adipose tissue, urine and more
  • Footprint-free reprogramming with feeder-free culture conditions
  • Highly optimized, high efficiency protocols ideal for iPSC banking/ iPSC repositories

Expanded characterization service available for more advanced profiling of your iPSC lines.

Technical Details

Stem cell research has made leaps-and-bounds since the mid-1990s with the derivation of human embryonic stem cells (hESCs), the establishment of human induced pluripotent stem cells (hiPSCs) in 2007, the directed-differentiation into preferred somatic lineages, and more recently clinical trials for cell replacement therapy. While the technology is making its initial foray into cell regeneration therapies, there is still intense, on-going research to understand the far-reaching implications of this technology and to fine-tune the protocols for directed-differentiation to various cell lineages; maintain genetic stability of cells during reprogramming, expansion and differentiation; and study the immunogenic potential of iPSCs and derived cells in transplantation/ cell regeneration medicine.    

The reprogramming of iPSCs from patient samples has enabled the generation of scalable, disease-relevant cell line models for hard-to-source and rare diseases, thus providing a valuable research tool to improve our understanding of disease biology and with the potential to develop treatment for essentially any disorder. As an example, research and drug discovery for several orphan diseases and neurodegenerative diseases such as Alzheimer’s (AD), Parkinson’s disease (PD), Multiple Sclerosis (MS), has lagged behind cancer and metabolic disease areas due to lack of physiologically relevant, easily sourced and affordable disease models that lead to successful translation of results from bench-to-bedside. The development of iPSCs and its directed-differentiation to neuronal lineage cells (neurons and glial cells) has offered biomedical research an unlimited source of clinically relevant cell line models that has advantages of immortalized cell line and culture while retaining the genetic and phenotypic characteristics or primary cells.  The iPSC-derived cell line models are able to recapture disease phenotypes and are ideal disease models for drug target discovery and drug screening, drug toxicity screening and in personalized medicine. The iPSC technology has been evolving rapidly in the last decade with differentiation to numerous cell lineages, organ-in-a-chip, clinical trials, and more. However, this technology still requires technical expertise even to handle something as basic as generating iPSCs from disease patient samples (where the disease phenotype affects culture characteristics, reprogramming efficiency, single cell cloning, differentiation capabilities and more).

Applied StemCell as one of the leaders in stem cell technology and earliest service provider for iPSC related services knows how to handle and reprogram iPSCs from both healthy and disease patient samples. We use highly efficient reprogramming procedures for generating high quality iPSCs: with non-integrating mRNA/ episomal/ viral vectors, or retroviral-based reprogramming protocols, and feeder-free/ xeno-free culturing conditions.  Let Applied StemCell’s stem cell experts generate iPSCs for you from your patient samples, using our optimized protocols and efficient workflows so you can enjoy stress-free research:

  • High reprogramming efficiency (>95% success rate)
  • From a variety of healthy/ disease patient biological samples (see table below)
  • Footprint-free, feeder-free, xeno-free protocols
  • iPSCs characterized for morphology and pluripotency markers
  • Additional characterization such as HLA-typing, G-banding/karyotyping, RT-PCR, STR profiling, directed-differentiation are also available. 

Optional: retroviral reprogramming, feeder-free culture protocols are also available

We offer iPSC generation services from a variety of patient samples:

Skin (dermal) fibroblast

Hematopoietic stem cells (HSCs)


Peripheral blood mononuclear cells (PBMCs)

Mesenchymal stem cells (MSCs)

Hair follicles

Cord blood cells (CD34+)

Adipose-derived stem cells (ADSCs)

Human umbilical vein endothelial cells (HUVEC)

We also offer other integrated services to give you a one-stop shop experience


iPSC differentiation: We can also help you expand your cell models to include iPSC differentiated cell lineages from same parental iPSC lines (isogenic cell lines):

Neural Stem Cells (NSCs) & Neurons (dopaminergic, cortical, motor, glutamatergic. GABAergic

Hematopoietic progenitor cells, T cells, B cells, NK cells, RBCs, macrophage

Retinal pigment epithelial cells (RPE)


Epithelial cells (Lung)


Endothelial cells (Blood brain barrier, BBB)

Hair follicle cells

Muscle cells (myoblast, smooth muscle cells)

Mesenchymal stem cells (MSCs)

Don’t see the information you may be looking for? Please do ask us about it. We have an excellent team of scientists with expertise in multiple aspects of iPSC and stem cell technologies. We will find you a solution to your question.

The combination of biorelevancy, scalability and high-throughput capabilities of iPSC-derived cell line models has empowered rapid drug screening while reducing cost by lessening the dependency on animal models, increasing screening efficiency, and therefore limiting costly late-stage drug attritions. Applied StemCell also provides iPSC-based neurotoxicity screening for your early-stage drug candidates as well as drug efficacy screening for CNS drugs, immunotherapies and more.


  • Jang, Y., Choi, J., Park, N., Kang, J., Kim, M., Kim, Y., & Ju, J. H. (2019). Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering. Experimental & Molecular Medicine, 51(1), 3.
  • Ilic, D. (2019). Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions in October 2018. Regenerative medicine, 14(2), 85-92.
  • Allende, M. L., Cook, E. K., Larman, B. C., Nugent, A., Brady, J. M., Golebiowski, D., ... & Proia, R. L. (2018). Cerebral organoids derived from Sandhoff disease induced pluripotent stem cells exhibit impaired neurodifferentiation. Journal of Lipid Research, jlr-M081323.
  • Field, A. R., Jacobs, F. M., Fiddes, I. T., Phillips, A. P., Reyes-Ortiz, A. M., LaMontagne, E., ... & Hauessler, M. (2019). Structurally Conserved Primate LncRNAs Are Transiently Expressed during Human Cortical Differentiation and Influence Cell-Type-Specific Genes. Stem cell reports.
Have Questions?

An Applied StemCell technical expert is happy to help, contact us today!